HypocalcemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

691 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp49

Immediate priorities

›Airway and breathing threats

›Laryngospasm recognition

›Stridor or inspiratory wheeze

›Progressive respiratory distress

›Seizure activity

›Generalized tonic-clonic

›Focal motor seizure from hypocalcemia

›If laryngospasm or airway compromise, immediate airway control

›Rapid sequence intubation preparation

›IV calcium gluconate concurrently

›Cardiac monitoring

›QTc prolongation on ECG

›Risk of torsades de pointes

›Risk of ventricular fibrillation

›Hemodynamic instability

›Hypocalcemic cardiomyopathy with depressed LVEF

›Reversible with calcium repletion

›Continuous telemetry mandatory for serum calcium <1.75 mmol/l

Stabilization

›IV access and resuscitation

›Peripheral IV for calcium gluconate

›Calcium chloride requires central line

›Peripheral extravasation causes tissue necrosis

›Cardiac monitor and pulse oximetry

›Continuous during IV calcium infusion

›QTc trending

›Initial calcium repletion in severe/symptomatic hypocalcemia

02History/hx79

Symptom characterization

›Core neuromuscular symptoms

›Perioral numbness and tingling

›Earliest and most common symptom

›Fingertip paresthesias associated

›Muscle cramps and spasms

›Carpopedal spasm

›Generalized muscle stiffness

›Tetany

›Spontaneous or provoked carpopedal spasm

›Distinguishes from simple paresthesias

›Cardiac and respiratory symptoms

›Palpitations

›QTc prolongation association

›Syncope if arrhythmia

›Dyspnea or wheezing

›Laryngospasm or bronchospasm

›Stridor as alarm feature

›Neuropsychiatric symptoms

›Seizures

›May be presenting symptom especially in neonates

›New onset unexplained seizure prompts calcium check

›Confusion or irritability

›Anxiety and emotional instability

›Depression in chronic hypocalcemia

Chronology and acuity

›Acute vs chronic onset

›Acute presentation

›Post-surgical (thyroidectomy, parathyroidectomy) within days

›Massive blood transfusion (citrate chelation)

›Critical illness or sepsis

›Chronic presentation

›Longstanding vitamin D deficiency

›CKD progressive course

›Gradual onset dry skin, brittle nails, dental abnormalities

›Surgical and procedural history

›Recent anterior neck surgery

›Thyroidectomy (most common cause of hypoparathyroidism — 75% of cases)

›Parathyroidectomy or radical neck dissection

›Timing of symptom onset after surgery

›Transient hypoparathyroidism typically resolves within weeks

›Permanent hypoparathyroidism if persistent beyond 6 months

Risk factors and exposures

›Medication review

›Antiresorptives

›Denosumab — highest risk; cumulative incidence ~41% in dialysis patients

›IV zoledronate > oral bisphosphonates

›Other causative agents

›Calcimimetics (cinacalcet)

›Loop diuretics (furosemide) — renal calcium wasting

›PPIs — via hypomagnesemia and impaired calcium absorption

›Cisplatin, aminoglycosides, foscarnet

›Medical history

›CKD stage and dialysis status

›Impaired 1,25(OH)2D production

›Hyperphosphatemia driving calcium depression

›Malabsorptive conditions

›Celiac disease, inflammatory bowel disease

›Gastric bypass or short bowel syndrome

›Malignancy

›Tumor lysis syndrome

›Osteoblastic metastases

›Recent chemotherapy

›Dietary and lifestyle factors

›Calcium and vitamin D intake

›Dairy avoidance or veganism

›Sun avoidance (vitamin D deficiency risk)

›Alcohol use

›Hypomagnesemia association

›Impaired PTH secretion

›Pancreatitis history

›Calcium saponification mechanism

Family history

›Hereditary and genetic risks

›Family history of hypocalcemia or early seizures

›CaSR activating mutations (autosomal dominant hypocalcemia type 1)

›GNA11 mutations

›Genetic syndromes

›22q11.2 deletion (DiGeorge syndrome) — hypoparathyroidism

›MEN syndromes

›Autoimmune polyendocrinopathy

›APECED syndrome (candidiasis, adrenal insufficiency, hypoparathyroidism)

›Family history of autoimmune thyroid or adrenal disease

03Physical Exam/exam49

Vital signs and general appearance

›Hemodynamic status

›Blood pressure

›Hypotension in severe or cardiomyopathy cases

›Tachycardia as compensatory response

›Respiratory rate and effort

›Stridor or increased work of breathing indicating laryngospasm

›Wheezing from bronchospasm

›General appearance

›Level of consciousness

›Confusion or agitation

›Seizure activity

›Muscle tone and activity

›Spontaneous tetany or rigidity

›Fasciculations

Neuromuscular signs

›Provocative signs

›Chvostek sign

›Facial twitching on tapping facial nerve anterior to ear

›Present in up to 25% of normals — limited specificity

›Trousseau sign

›Carpopedal spasm within 3 minutes of inflating BP cuff above systolic

›More specific than Chvostek for hypocalcemia

›Neurological exam

›Deep tendon reflexes

›Hyperreflexia characteristic of hypocalcemia

›Clonus may be present

›Cranial nerves

04Differential Diagnosis/ddx50

Low or inappropriately normal PTH causes

›Hypoparathyroidism

›Postsurgical hypoparathyroidism

›ICD-10 E20.0

›Most common cause; 75% of hypoparathyroidism cases

›Autoimmune hypoparathyroidism

›ICD-10 E20.1

›Isolated or as part of APECED syndrome

›Genetic hypoparathyroidism

›22q11.2 deletion syndrome (DiGeorge)

›CaSR activating mutations (autosomal dominant hypocalcemia type 1)

›HDR syndrome (hypoparathyroidism, deafness, renal anomaly)

›Infiltrative or destructive

›Hemochromatosis, Wilson disease

›Metastatic malignancy to parathyroids

Elevated PTH causes

›Vitamin D deficiency

›ICD-10 E55.9

›Most common cause of hypocalcemia overall

›25-OH-D <50 nmol/l associated with secondary hyperparathyroidism

›Dietary deficiency, malabsorption, sun avoidance

›CKD-mineral bone disorder

›ICD-10 N18.x with E83.59

›Impaired renal 1-alpha-hydroxylation of vitamin D

›Hyperphosphatemia amplifies calcium depression

›Tertiary hyperparathyroidism possible with longstanding disease

›Pseudohypoparathyroidism

›ICD-10 E20.1

05Laboratory Tests/lt57

Core calcium assessment

›Serum calcium interpretation

›Total serum calcium

›Hypocalcemia defined as <2.12 mmol/l

›Severe hypocalcemia <1.75 mmol/l requiring urgent intervention

›Albumin-corrected calcium

›Corrected Ca = Measured Ca + 0.02 x (40 - albumin in g/l)

›Corrects for hypoalbuminemia masking true calcium status

›Ionized calcium (preferred in critical illness)

›Hypocalcemia defined as ionized Ca <1.15 mmol/l

›Albumin-adjusted calcium correlates poorly with ionized calcium in critically ill, dialysis, and elderly patients

›Available on ABG analyzer for rapid ED assessment

›PTH measurement

›Intact PTH (iPTH) central to etiology workup

›Low or inappropriately normal PTH indicates hypoparathyroidism

›Elevated PTH indicates secondary causes (vitamin D deficiency, CKD, pseudohypoparathyroidism)

›PTH drawn simultaneously with calcium for interpretation

›Class I recommendation for etiologic workup

Vitamin D and phosphorus

›Vitamin D status

›25-hydroxyvitamin D (25-OH-D)

›Best marker of vitamin D stores

›Target >75 nmol/l to suppress secondary hyperparathyroidism

›1,25-dihydroxyvitamin D (calcitriol)

›Indicated in CKD or suspected vitamin D metabolism disorder

›May be low in hypoparathyroidism despite normal 25-OH-D

›Phosphorus

›Elevated in hypoparathyroidism and pseudohypoparathyroidism

06Diagnostic Tests/dt69

Scoring Systems

›Hypocalcemia severity stratification

›Mild hypocalcemia

›Corrected calcium 2.0-2.12 mmol/l

›Asymptomatic or mild paresthesias only

›Moderate hypocalcemia

›Corrected calcium 1.75-2.0 mmol/l

›Symptomatic: cramps, paresthesias, positive Chvostek or Trousseau

›Severe hypocalcemia

›Corrected calcium <1.75 mmol/l

›Or any level with tetany, seizures, laryngospasm, QTc prolongation, or hemodynamic instability

›Requires immediate IV calcium and cardiac monitoring

›Clinical decision points

›PTH-based etiologic algorithm

›Low PTH branch: hypoparathyroidism workup

›High PTH branch: vitamin D, renal, pseudohypoparathyroidism workup

›Normal PTH: consider functional causes (hypomagnesemia, CaSR mutations)

›Underrecognition in ED

›Identified and documented in only 35% of ED cases in one retrospective study

›Calcium replacement administered in less than half of severe cases

›41.9% of patients with severe hypocalcemia re-presented within 1 year

MRI

›MRI brain indications in hypocalcemia

›Basal ganglia calcifications (chronic hypoparathyroidism)

›CT preferred for calcification detection

›MRI may show signal abnormalities in severe cases

›Seizure workup

›MRI brain when seizures not clearly attributable to metabolic cause

07Disposition/dispo51

ICU and telemetry admission

›ICU indications

›Severe life-threatening manifestations

›Seizures refractory to initial calcium

›Laryngospasm or airway compromise

›Ventricular arrhythmia from QTc prolongation

›Hemodynamic instability

›Hypocalcemic cardiomyopathy with depressed LVEF

›Vasopressor requirement

›Continuous IV calcium infusion required

›Frequent ionized calcium monitoring needed

›Telemetry for QTc trending

›Telemetry ward admission

›Moderate symptomatic hypocalcemia

›Symptomatic at presentation but stabilizing

›QTc borderline prolonged

›Post-thyroidectomy declining calcium trend

›Serial calcium checks every 4-6 hours

›High risk for rapid decline in first 24-48 hours

Discharge criteria

›Outpatient management criteria

›Asymptomatic or mild symptoms

›Controlled on oral calcium and calcitriol

›Corrected calcium >2.0 mmol/l and stable

›Etiology identified and addressable

›Vitamin D deficiency with supplementation initiated

›Medication-induced with offending agent modified

›Reliable follow-up arranged

08Treatment/t85

Acute severe hypocalcemia

›IV calcium gluconate (first-line acute)

›Initial bolus

›Calcium gluconate 1-2 g (10-20 mL of 10% solution) IV

›Diluted in 50 mL D5W, infused over 10-20 minutes

›Provides 93-186 mg elemental calcium per dose

›Peripheral IV acceptable

›Onset and duration

›Effect within minutes but short-lived (1-2 hours)

›Must be followed by continuous infusion to prevent recurrence

›Continuous infusion for maintenance

›Calcium gluconate 6-8 g in 500 mL D5W at 50 mL/hour

›Titrate to ionized calcium target 1.15-1.3 mmol/l

›Recheck ionized calcium every 1-2 hours during infusion

›IV calcium chloride (alternative for cardiac arrest only)

›Calcium chloride 1 g IV (10 mL of 10% solution)

›Provides 270 mg elemental calcium

›Central line required — risk of tissue necrosis peripherally

›Three times more elemental calcium than gluconate per equivalent volume

›Reserved for cardiac arrest or when central access available

›Faster ionization compared to gluconate

Magnesium repletion

›Concurrent magnesium replacement essential

›Hypomagnesemia causes refractory hypocalcemia

›Impairs PTH secretion

›Impairs end-organ PTH response

›IV magnesium sulfate

›MgSO4 1-2 g IV over 15-30 minutes for severe deficiency

›Follow with 0.5 g/hour infusion until normalized

›Oral magnesium oxide

›Magnesium oxide 400 mg PO twice daily for mild deficiency

›Diarrhea common at higher doses

Calcitriol and vitamin D

›Calcitriol (active vitamin D)

›Acute/subacute initiation

›Calcitriol 0.25-0.5 mcg PO twice daily

›Preferred active vitamin D in hypoparathyroidism

›Onset of action 1-3 days

›Dose adjustment

›Increase by 0.25 mcg increments based on calcium response

›Maximum typically 2-3 mcg/day in divided doses

›Gradual reduction once stable to avoid rebound hypercalcemia

›Cholecalciferol or ergocalciferol

›Vitamin D deficiency treatment

›Cholecalciferol 1000-4000 IU daily for maintenance

›High-dose loading if severe deficiency (25-OH-D <25 nmol/l)

›Goal 25-OH-D level

›Target >75 nmol/l to suppress secondary hyperparathyroidism

›Recheck 25-OH-D in 3 months

Oral calcium supplementation

›Calcium carbonate

›Dose

›1-3 g elemental calcium daily in divided doses with meals

›Requires acidic environment for absorption

›Use with caution in

›Patients on PPIs (impaired absorption — use calcium citrate instead)

›Post-gastric bypass or achlorhydria

›Calcium citrate (preferred in specific populations)

›Dose

›1-3 g elemental calcium daily in divided doses

›Does not require acid for absorption

›Preferred over carbonate in

›PPI users, post-bariatric surgery, achlorhydria

›Elderly with reduced gastric acid

›Dosing principles

›Divide doses (maximum 500-600 mg elemental calcium per dose for absorption)

›Larger doses poorly absorbed

›Separate from levothyroxine by at least 1 hour before or 3 hours after

›Calcium inhibits levothyroxine absorption

›Calcium gluconate incompatible with phosphate or bicarbonate-containing fluids

Adjunctive and advanced therapies

›Thiazide diuretics (adjunctive)

›Hydrochlorothiazide 12.5-50 mg daily

›Reduces renal calcium excretion

›Useful in refractory hypocalcemia or hypercalciuria on supplementation

›Monitor potassium and sodium

›Combined with low-sodium diet for enhanced calcium retention

›PTH replacement therapy

›rhPTH(1-84) — teriparatide analog (Natpara)

›Indicated for chronic hypoparathyroidism refractory to conventional therapy

›Reduces supplementation burden and hypercalciuria risk

›Subcutaneous injection once daily

›Not widely available; specialist-initiated

›CKD-specific adjustments

›Avoid excess calcium supplementation in CKD (limit to 800-1000 mg/day elemental calcium from all sources)

›Risk of vascular calcification

›Phosphate binders if hyperphosphatemia present

›Non-calcium binders preferred in CKD

›Calcitriol dose adjustment for eGFR

›Reduced doses required as renal function declines

09Special Populations/sp75

Pregnancy

›Pregnancy considerations

›Physiologic calcium changes

›Serum calcium normally falls in pregnancy due to hemodilution

›Ionized calcium remains stable — preferred measure

›PTH normally suppressed in first trimester then rises

›Maternal risk

›Tetany and laryngospasm risk to mother

›Uncontrolled hypocalcemia risks preterm labour

›Fetal risk

›Compensatory fetal hyperparathyroidism from maternal hypocalcemia

›Neonatal bone disease risk

›Management in pregnancy

›Calcium gluconate IV safe for acute severe hypocalcemia

›Standard dosing applies

›Fetal monitoring during IV infusion

›Calcitriol generally safe in pregnancy

›Monitor closely — requirements may change across trimesters

›Dose adjustments often needed

›Oral calcium supplementation safe

›1000-1300 mg elemental calcium daily recommended

›Calcium citrate preferred to avoid gastrointestinal intolerance

Geriatric

›Geriatric considerations

›Higher prevalence of vitamin D deficiency

›Reduced skin synthesis, institutionalization, dark pigmentation

›Frequent contributor to falls and fractures

›Polypharmacy risk

›Loop diuretics and PPIs among most prescribed drugs

›Drug-induced hypocalcemia underrecognized

›Denosumab risk

›FDA black box warning for severe hypocalcemia in dialysis patients

›Elderly dialysis-dependent females at highest risk

›Modified management in older adults

›Calcium citrate preferred over carbonate

›Reduced gastric acid production with age

›Better absorbed without food acid requirement

›Calcitriol dosing caution

›Monitor for hypercalcemia and hypercalciuria

›Renal function decline affects dose requirements

›Fall and fracture risk assessment

›Neuromuscular symptoms from hypocalcemia increase fall risk

›Bone density assessment in chronic disease

›Disposition bias toward admission

›Atypical presentation (delirium, weakness)

›Limited home monitoring capacity

Pediatrics

›Neonatal hypocalcemia

›Early neonatal (first 72 hours)

›Prematurity and maternal diabetes most common causes

›Functional hypoparathyroidism from suppression by maternal hypercalcemia

›Late neonatal (day 5-10)

›High phosphate formula feeding

›Maternal vitamin D deficiency

›Seizures as presenting symptom common in neonates

›Jitteriness, irritability, apnea

›Hypocalcemia must be ruled out in any neonatal seizure

›Pediatric dosing

›IV calcium gluconate for acute symptomatic hypocalcemia

›50-100 mg/kg (0.5-1 mL/kg of 10% solution) IV over 5-10 minutes

›Maximum single dose 1 g

›Followed by maintenance infusion 50-75 mg/kg/day elemental calcium

›Oral calcium carbonate supplementation

›Dose based on weight and age

›25-65 mg/kg/day elemental calcium in divided doses

›Calcitriol in pediatrics

›0.01-0.08 mcg/kg/day (maximum 0.5-2 mcg/day)

›Adjust based on serum calcium response

›Genetic causes priority in children

›22q11.2 deletion (DiGeorge syndrome)

›Hypoparathyroidism, conotruncal heart defects, immune deficiency

›FISH or chromosomal microarray testing

›2025 AAP health supervision guidelines updated for 22q11.2 management

›CaSR activating mutations (autosomal dominant hypocalcemia type 1)

›Family screening recommended

›Avoid over-supplementation — high risk of nephrocalcinosis

›Genetic panel for non-surgical pediatric hypoparathyroidism

›GCM2, PTH, GNA11, CaSR, GATA3 genes

10Background/b74

Epidemiology

›Prevalence and incidence

›Vitamin D deficiency as commonest cause globally

›Affects >1 billion people worldwide

›Secondary hyperparathyroidism and hypocalcemia secondary consequence

›Hypoparathyroidism prevalence

›Approximately 1 in 4000 in developed countries

›Post-surgical accounts for ~75% of all hypoparathyroidism cases

›ED hypocalcemia data

›Severe hypocalcemia identified and documented in only 35% of ED cases

›Calcium replacement given in <50% of severe cases

›41.9% re-presented within 1 year (Haidinger et al. 2025)

›High-risk populations

›Post-thyroidectomy patients

›Transient hypoparathyroidism in up to 30-40% after total thyroidectomy

›Permanent hypoparathyroidism in 1-3%

›Dialysis patients on denosumab

›Cumulative incidence of severe hypocalcemia ~41% in dialysis cohorts

›FDA-required REMS program for denosumab in CKD

Pathophysiology

›Calcium homeostasis mechanisms

›Normal regulation

›PTH released from parathyroid glands in response to low ionized calcium

›PTH increases renal calcium reabsorption and stimulates 1-alpha-hydroxylase

›1,25(OH)2D (calcitriol) increases intestinal calcium and phosphorus absorption

›CaSR role

›Calcium-sensing receptor on parathyroid cells detects ionized calcium

›Activating CaSR mutations suppress PTH — causing hypocalcemia

›Target of calcimimetics (cinacalcet) — mechanism of drug-induced hypocalcemia

›Cardiac effects

›QTc prolongation mechanism

›Calcium modulates cardiac action potential phase 2 (plateau)

›Hypocalcemia prolongs ST segment specifically (not T-wave)

›QTc inversely correlates with serum calcium level

›Hypocalcemic cardiomyopathy

›Reversible dilated cardiomyopathy with severely depressed LVEF

›Reported with serum calcium <1.5 mmol/l

›Resolves with calcium normalization (systematic review Newman et al. 2014)

›Neuromuscular effects

›Decreased extracellular calcium increases neuronal membrane excitability

›Reduces action potential threshold

›Results in spontaneous nerve and muscle depolarization

›Tetany spectrum

›Paresthesias to carpopedal spasm to laryngospasm to generalized seizures

›Severity correlates with rate of fall as well as absolute level

Therapeutic Considerations

›Etiologic treatment principles

›Hypoparathyroidism management

›Oral calcium and calcitriol foundation of chronic management

›Goal: maintain serum calcium in low-normal range (2.0-2.25 mmol/l)

›Avoid hypercalcemia and minimize hypercalciuria (target urine Ca <6.25 mmol/24h)

›Vitamin D deficiency treatment

›Cholecalciferol preferred over ergocalciferol for repletion

›Calcitriol not appropriate for vitamin D deficiency alone (bypasses regulatory steps)

›CKD management

›Limit dietary phosphorus and use phosphate binders

›Calcitriol or alfacalcidol for impaired 1-alpha-hydroxylation

›Limit total calcium intake to 800-1000 mg/day

›Drug interaction considerations

›Calcium and levothyroxine

›Calcium inhibits levothyroxine absorption

›Separate by at least 1 hour before or 3 hours after levothyroxine

›Calcium gluconate incompatibilities

›Incompatible with phosphate-containing fluids (precipitates)

›Incompatible with bicarbonate-containing fluids

›Thiazide diuretics as adjunct

›Enhance renal calcium reabsorption

›Particularly useful in hypoparathyroidism to reduce supplementation requirements

›Monitoring framework

›Acute phase

›Ionized calcium every 1-2 hours during IV infusion

›Continuous ECG monitoring

›Magnesium recheck at 4-6 hours

›Chronic phase

›Serum calcium and creatinine every 3-4 months

›24-hour urine calcium periodically

›Renal ultrasound every 1-2 years in chronic supplementation

11Patient Discharge Instructions/pdi26

copy discharge instructions

›Hypocalcemia home care

›Take calcium supplements exactly as prescribed

›With meals (calcium carbonate) or without food (calcium citrate)

›Divide doses — no more than 500 mg elemental calcium at one time

›Take calcitriol as prescribed without stopping abruptly

›Abrupt discontinuation can cause severe rebound hypocalcemia

›Separate calcium from thyroid medication (levothyroxine) by at least 1 hour

›Dietary recommendations

›Calcium-rich foods: dairy products, fortified foods, leafy greens

›Aim for 1000-1300 mg dietary calcium daily from all sources

›Adequate vitamin D from fortified foods, fatty fish, safe sun exposure

›Avoid excess phosphorus: processed foods, colas — worsens calcium absorption

›Adequate hydration to reduce kidney stone risk from supplementation

›Warning signs — return to emergency immediately for

›Muscle spasms, cramps, or stiffness that are severe or worsening

›Numbness or tingling around the mouth or fingertips that is severe

›Difficulty breathing, throat tightness, or stridor

›Seizures or loss of consciousness

›Palpitations, chest pain, or fainting

›Confusion or unusual mental changes

›Follow-up

›Blood calcium recheck within 24-48 hours after discharge

›Earlier if symptoms worsen

›Follow-up appointment with endocrinologist or family doctor within 1-2 weeks

›If post-thyroid surgery, surgeon follow-up as instructed

›Medication dose adjustments expected — do not change doses without medical guidance

12References/r27

Guidelines and key sources

›Primary evidence sources

›Pepe J et al. Diagnosis and Management of Hypocalcemia. Endocrine. 2020. PMID 32367335

›Comprehensive review of acute and chronic management

›Drug dosing thresholds and ECG monitoring guidance

›Bove-Fenderson E, Mannstadt M. Hypocalcemic Disorders. Best Practice and Research Clinical Endocrinology and Metabolism. 2018. PMID 30449546

›PTH-based diagnostic algorithm

›Epidemiology and etiology classification

›Sell J, Ramirez S, Partin M. Parathyroid Disorders. American Family Physician. 2022. PMID 35289573

›Practical clinical approach including medication causes

›Haidinger M et al. Severe Hypocalcemia in the Emergency Department. Internal and Emergency Medicine. 2025. PMID 38839645

›Retrospective cohort: prevalence, treatment rates, 1-year re-presentation data

›Specialty guidelines

›Orloff LA et al. American Thyroid Association Statement on Postoperative Hypoparathyroidism. Thyroid. 2018

›Post-surgical hypocalcemia monitoring and management

›Mannstadt M et al. Hypoparathyroidism: Genetics and Diagnosis. Journal of Bone and Mineral Research. 2022. PMID 36375809

›Genetic panel recommendations and diagnostic criteria

›Gafni RI, Collins MT. Hypoparathyroidism. New England Journal of Medicine. 2019

›Chronic hypoparathyroidism management including rhPTH(1-84)

›Scheuerle AE et al. Health Supervision for Children With 22q11.2 Deletion Syndrome. Pediatrics. 2025

›Updated AAP clinical report for DiGeorge syndrome management

›Coding references

›ICD-10 codes

›E20.0 Idiopathic hypoparathyroidism

›E20.1 Pseudohypoparathyroidism

›E55.9 Vitamin D deficiency unspecified

›E83.51 Hypocalcemia

›E89.2 Hypoparathyroidism following procedure

Learn More: Hypocalcemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.